The effect of temazepam on assessment of severity of obstructive sleep apnea by polysomnography

Research output: Contribution to journalArticle

1 Citation (Scopus)
57 Downloads (Pure)

Abstract

Purpose: To determine the effect of temazepam on assessment of the severity of obstructive sleep apnea (OSA) by polysomnography (PSG). Methods: Analysis of diagnostic laboratory-PSG studies was performed in OSA patients who were administered temazepam (10 mg) to facilitate sleep (“temazepam group”, n = 73) and in OSA patients (matched for age, gender, body mass index and study date) in whom temazepam was not administered (“control group”, n = 73). Sleep- and respiratory-related variables were compared between the groups for the (i) first 3 h of study following temazepam in the temazepam group (when peak blood concentration is expected) or following lights out in the control group, and (ii) entire study duration. Results: Within the first 3 h, no differences in sleep-related variables were observed between the groups. Over the entire study duration, the temazepam group had a reduced total sleep time compared to the control group, likely due to the overnight sleep difficulties that led to its use. Whether measured during the first 3 h of study or over the entire study duration, no significant differences were detected between the groups for any respiratory-related variable, including apnea hypopnea index, arousal index, oxygen desaturation, apnea index, hypopnea index, and event duration. When patients were considered in terms of OSA severity, decreased arousal index was noted in the temazepam group over the entire study duration, but only in those with severe OSA. Conclusion: Oral administration of 10 mg of temazepam during the course of PSG does not systematically affect assessment of the severity of OSA by PSG.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalSLEEP AND BREATHING
Volume23
Issue number1
Early online date19 Mar 2018
DOIs
Publication statusPublished - Mar 2019

Fingerprint

Temazepam
Polysomnography
Obstructive Sleep Apnea
Sleep
Apnea
Arousal
Control Groups
Oral Administration
Body Mass Index
Oxygen
Light

Cite this

@article{616161a86d794aee97b73eaa961b11a4,
title = "The effect of temazepam on assessment of severity of obstructive sleep apnea by polysomnography",
abstract = "Purpose: To determine the effect of temazepam on assessment of the severity of obstructive sleep apnea (OSA) by polysomnography (PSG). Methods: Analysis of diagnostic laboratory-PSG studies was performed in OSA patients who were administered temazepam (10 mg) to facilitate sleep (“temazepam group”, n = 73) and in OSA patients (matched for age, gender, body mass index and study date) in whom temazepam was not administered (“control group”, n = 73). Sleep- and respiratory-related variables were compared between the groups for the (i) first 3 h of study following temazepam in the temazepam group (when peak blood concentration is expected) or following lights out in the control group, and (ii) entire study duration. Results: Within the first 3 h, no differences in sleep-related variables were observed between the groups. Over the entire study duration, the temazepam group had a reduced total sleep time compared to the control group, likely due to the overnight sleep difficulties that led to its use. Whether measured during the first 3 h of study or over the entire study duration, no significant differences were detected between the groups for any respiratory-related variable, including apnea hypopnea index, arousal index, oxygen desaturation, apnea index, hypopnea index, and event duration. When patients were considered in terms of OSA severity, decreased arousal index was noted in the temazepam group over the entire study duration, but only in those with severe OSA. Conclusion: Oral administration of 10 mg of temazepam during the course of PSG does not systematically affect assessment of the severity of OSA by PSG.",
keywords = "AHI, Airway collapsibility, Airway obstruction, Benzodiazepine, Respiratory sleep disorder, Sedatives",
author = "Walsh, {Jennifer H.} and Carolyn Visser and Kathleen Maddison and Chrianna Bharat and Hillman, {David R.} and Eastwood, {Peter R.}",
year = "2019",
month = "3",
doi = "10.1007/s11325-018-1653-3",
language = "English",
volume = "23",
pages = "49--56",
journal = "SLEEP AND BREATHING",
issn = "1520-9512",
publisher = "Springer-Verlag London Ltd.",
number = "1",

}

The effect of temazepam on assessment of severity of obstructive sleep apnea by polysomnography. / Walsh, Jennifer H.; Visser, Carolyn; Maddison, Kathleen; Bharat, Chrianna; Hillman, David R.; Eastwood, Peter R.

In: SLEEP AND BREATHING, Vol. 23, No. 1, 03.2019, p. 49-56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of temazepam on assessment of severity of obstructive sleep apnea by polysomnography

AU - Walsh, Jennifer H.

AU - Visser, Carolyn

AU - Maddison, Kathleen

AU - Bharat, Chrianna

AU - Hillman, David R.

AU - Eastwood, Peter R.

PY - 2019/3

Y1 - 2019/3

N2 - Purpose: To determine the effect of temazepam on assessment of the severity of obstructive sleep apnea (OSA) by polysomnography (PSG). Methods: Analysis of diagnostic laboratory-PSG studies was performed in OSA patients who were administered temazepam (10 mg) to facilitate sleep (“temazepam group”, n = 73) and in OSA patients (matched for age, gender, body mass index and study date) in whom temazepam was not administered (“control group”, n = 73). Sleep- and respiratory-related variables were compared between the groups for the (i) first 3 h of study following temazepam in the temazepam group (when peak blood concentration is expected) or following lights out in the control group, and (ii) entire study duration. Results: Within the first 3 h, no differences in sleep-related variables were observed between the groups. Over the entire study duration, the temazepam group had a reduced total sleep time compared to the control group, likely due to the overnight sleep difficulties that led to its use. Whether measured during the first 3 h of study or over the entire study duration, no significant differences were detected between the groups for any respiratory-related variable, including apnea hypopnea index, arousal index, oxygen desaturation, apnea index, hypopnea index, and event duration. When patients were considered in terms of OSA severity, decreased arousal index was noted in the temazepam group over the entire study duration, but only in those with severe OSA. Conclusion: Oral administration of 10 mg of temazepam during the course of PSG does not systematically affect assessment of the severity of OSA by PSG.

AB - Purpose: To determine the effect of temazepam on assessment of the severity of obstructive sleep apnea (OSA) by polysomnography (PSG). Methods: Analysis of diagnostic laboratory-PSG studies was performed in OSA patients who were administered temazepam (10 mg) to facilitate sleep (“temazepam group”, n = 73) and in OSA patients (matched for age, gender, body mass index and study date) in whom temazepam was not administered (“control group”, n = 73). Sleep- and respiratory-related variables were compared between the groups for the (i) first 3 h of study following temazepam in the temazepam group (when peak blood concentration is expected) or following lights out in the control group, and (ii) entire study duration. Results: Within the first 3 h, no differences in sleep-related variables were observed between the groups. Over the entire study duration, the temazepam group had a reduced total sleep time compared to the control group, likely due to the overnight sleep difficulties that led to its use. Whether measured during the first 3 h of study or over the entire study duration, no significant differences were detected between the groups for any respiratory-related variable, including apnea hypopnea index, arousal index, oxygen desaturation, apnea index, hypopnea index, and event duration. When patients were considered in terms of OSA severity, decreased arousal index was noted in the temazepam group over the entire study duration, but only in those with severe OSA. Conclusion: Oral administration of 10 mg of temazepam during the course of PSG does not systematically affect assessment of the severity of OSA by PSG.

KW - AHI

KW - Airway collapsibility

KW - Airway obstruction

KW - Benzodiazepine

KW - Respiratory sleep disorder

KW - Sedatives

UR - http://www.scopus.com/inward/record.url?scp=85044247946&partnerID=8YFLogxK

U2 - 10.1007/s11325-018-1653-3

DO - 10.1007/s11325-018-1653-3

M3 - Article

VL - 23

SP - 49

EP - 56

JO - SLEEP AND BREATHING

JF - SLEEP AND BREATHING

SN - 1520-9512

IS - 1

ER -